# Study of Intravenous Erenumab in Patients With Status Migrainosus

> **NCT04920331** · PHASE1 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Status Migrainosus

## Interventions

- **BIOLOGICAL:** Erenumab

## Key facts

- **NCT ID:** NCT04920331
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-07
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No Participants Enrolled
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920331, "Study of Intravenous Erenumab in Patients With Status Migrainosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04920331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*